Michael Burgess
Chief Tech/Sci/R&D Officer presso TURNSTONE BIOLOGICS CORP.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Michael M.
Burgess is currently the Director & Chief Medical Officer at Turnstone Biologics Corp.
He is also a Member of The Royal College of Physicians and The Royal College of Paediatrics & Child Health.
Additionally, he serves as a Member-Supervisory Board at iOmx Therapeutics AG.
In his former positions, Dr. Burgess served as an Independent Director at Synlogic, Inc. from 2020 to 2024.
He was also the SVP-Discovery Medicine & Clinical Pharmacology at Bristol Myers Squibb Co. Furthermore, he held positions at Roche Holding AG, Hoffmann-La Roche, Inc., Roche Holding (UK) Ltd., and Roche Ltd., where he held various leadership roles in the field of oncology discovery and translational area.
Dr. Burgess received his graduate degree from the University of Bristol in 1989 and later obtained his doctorate from the same institution in 1999.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 16/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
SYNLOGIC INC
-.--% | 18/08/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Michael Burgess
| Società | Posizione | Inizio |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Chief Tech/Sci/R&D Officer | 01/10/2017 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
| The Royal College of Paediatrics & Child Health | Corporate Officer/Principal | - |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Director/Board Member | 20/07/2022 |
Precedenti posizioni note di Michael Burgess
| Società | Posizione | Fine |
|---|---|---|
| SYNLOGIC, INC. | Director/Board Member | 20/03/2024 |
| SPRINGWORKS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 16/09/2022 |
Roche Holding (UK) Ltd.
 Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Corporate Officer/Principal | 01/01/2010 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formazione di Michael Burgess
| University of Bristol | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ROCHE HOLDING AG | Health Technology |
| SYNLOGIC, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Holding (UK) Ltd.
Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Health Technology |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
- Borsa valori
- Insiders
- Michael Burgess
